Provectus Biopharmaceuticals Receives U.S. Patent Notice for Oral Rose Bengal Sodium in Leukemia

Provectus Biopharmaceuticals, Inc., based in Knoxville, TN, has announced a significant milestone in their pursuit of innovative cancer treatments. On May 2, 2024, the company revealed that the United States Patent and Trademark Office has allowed their patent application numbered 17/232,393. This patent, titled “Halogenated Xanthene Composition and Method for Treating Hematologic Cancers,” encompasses the use of Provectus's pharmaceutical grade rose bengal sodium (RBS) as a treatment option for both pediatric and adult leukemias. This application was previously known under the title “Composition and Method for Oral Treatment of Leukemia.”

The approval of this patent marks a pivotal moment for Provectus as it broadens the potential therapeutic applications of rose bengal sodium. Earlier in the year, Provectus had also announced other significant advancements, including patents related to RBS in virology, pediatric solid tumor cancers, and vaccines. These patents further strengthen the company's intellectual property portfolio and highlight the versatility of their lead compound.

Provectus’s collaboration with Innovate Calgary, the University of Calgary’s innovation company, and Dr. Aru Narendran, a prominent Professor at the University’s Cumming School of Medicine, has been crucial in achieving these milestones. Dr. Narendran, who holds expertise in Pediatrics, Oncology, Biochemistry, Molecular Biology, and Physiology and Pharmacology, is a co-inventor on all four of the recent patent awards.

Dominic Rodrigues, President and Vice Chairman of Provectus's Board of Directors, emphasized the company's commitment to advancing their cancer immunotherapy drug, PV-10, particularly for metastatic pancreatic cancer. Rodrigues also expressed confidence in the growing potential of rose bengal sodium when administered orally for treating various diseases.

Provectus Biopharmaceuticals is a clinical-stage biotechnology company focused on developing immunotherapy treatments derived from halogenated xanthenes, a class of synthetic small molecule immuno-catalysts. The company's flagship molecule, rose bengal sodium, is at the core of their research and development efforts.

The company’s medical science platform is extensive, featuring clinical development programs in oncology, dermatology, and ophthalmology. Additionally, Provectus is exploring in vivo proof-of-concept studies in fields such as oncology, hematology, full-thickness cutaneous wound healing, and canine cancers. Their research also includes in vitro discovery programs targeting infectious diseases, tissue regeneration and repair, and proprietary targets.

Provectus Biopharmaceuticals continues to demonstrate significant progress in the field of biotechnology, driven by their innovative approach to using halogenated xanthenes for various therapeutic applications. The recent patent approval for the treatment of hematologic cancers underscores the potential impact of rose bengal sodium in transforming cancer treatment paradigms.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!